APRESOLINE

This brand name is authorized in Canada, Ireland, Japan, New Zealand, Singapore, South Africa, UK.

Active ingredients

The drug APRESOLINE contains one active pharmaceutical ingredient (API):

1	Hydralazine UNII FD171B778Y - HYDRALAZINE HYDROCHLORIDE
	Hydralazine is a direct acting vasodilator which exerts its effects principally on the arterioles. Its precise mode of action is not known.
	Read more about Hydralazine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
APRESOLINE Solution for injection	MPI, CA: SPM	Health Products and Food Branch (CA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C02DB02	Hydralazine	C Cardiovascular system → C02 Antihypertensives → C02D Arteriolar smooth muscle, agents acting on → C02DB Hydrazinophthalazine derivatives
Discover more medicines within C02DB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	00723754
GB	Medicines & Healthcare Products Regulatory Agency	13912
IE	Health Products Regulatory Authority	12831
JP	医薬品医療機器総合機構	2142004B2163, 2142004F1053, 2142004F2025, 2142004F3056
NZ	Medicines and Medical Devices Safety Authority	2357
SG	Health Sciences Authority	00509P
ZA	Health Products Regulatory Authority	H/7.1.3/525, Q/7.1.3/180